Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Otsuka America Pharmaceutical Clear all
Completed Phase 1 Interventional

A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease

NCT00002337
View directory record Official record
Conditions
HIV Infections
Interventions
Vesnarinone
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Not applicable Interventional

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

NCT00002130
View directory record Official record
Conditions
HIV Infections
Interventions
Vesnarinone
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

NCT00337571
View directory record Official record
Conditions
Behavioral Symptoms, Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 11, 2026, 7:45 AM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

NCT02472652
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Abilify Maintena
Drug
Lead sponsor
Gazda, Thomas D., M.D., PC
Individual
Eligibility
18 Years to 40 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bullhead City, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

NCT01131169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
busulfan, melphalan and fludarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 72 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional

Aripiprazole Oral Acceptability Trial

NCT00101569
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
7
States / cities
Anaheim, California • National City, California • North Miami Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 4 Interventional Results available

POCone-UBiT-IR300 Pediatric Comparison Study

NCT01623154
View directory record Official record
Conditions
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions
Pranactin citric solution
Other
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
3 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • El Paso, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aripiprazole in Patients With Major Depressive Disorder

NCT00105196
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aripiprazole+ ADT, Placebo+ ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 11, 2026, 7:45 AM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

NCT00095524
View directory record Official record
Conditions
Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 4 Interventional

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

NCT00095810
View directory record Official record
Conditions
Parkinson's Disease, Psychoses
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

NCT00365859
View directory record Official record
Conditions
Autistic Disorder, Behavioral Symptoms
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
55
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 2 Interventional

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions
PB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048763
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Pletal
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
5 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Anchorage, Alaska • Fresno, California • Madera, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

NCT00095719
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
14
States / cities
Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional

Effect of Tolvaptan on Cognitive Function in Cirrhosis

NCT01556646
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Hyponatremia
Interventions
Tolvaptan
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 11, 2026, 7:45 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD

NCT02934932
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Brexpiprazole
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

NCT00002129
View directory record Official record
Conditions
HIV Infections
Interventions
Vesnarinone
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional

Aripiprazole in Patients With Acute Mania

NCT00095511
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
38
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Cerritos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional

A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

NCT00095758
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + Placebo, Antidepressant + Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Beverly Hills, California • Burbank, California • National City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan for Ascites in Cirrhotic Patients

NCT01292304
View directory record Official record
Conditions
Ascites, Cirrhosis
Interventions
Tolvaptan
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 11, 2026, 7:45 AM EDT
Completed Phase 3 Interventional Results available

Study for the Treatment of Crohn's Disease With Adacolumn

NCT00162942
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adacolumn, Sham
Device
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
28
States / cities
Phoenix, Arizona • Roseville, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 11, 2026, 7:45 AM EDT